BA
ACAD icon

Bridgewater Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Bridgewater Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.16M Buy
141,812
+3,633
+3% +$86.8K 0.01% 537
2025
Q4 		$3.69M Sell
138,179
-25,066
-15% -$599K 0.01% 615
2025
Q3 		$3.48M Buy
+163,245
New +$3.86M 0.01% 577
2022
Q3 		– Sell
-10,918
Closed -$154K – 868
2022
Q2 		$154K Buy
10,918
+1,929
+21% +$36K ﹤0.01% 978
2022
Q1 		$218K Buy
+8,989
New +$218K ﹤0.01% 957

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bridgewater Associates's ACAD Position: Q1 2026 in Review

Bridgewater Associates increased its Acadia Pharmaceuticals (ACAD) stake by 2.6% in Q1 2026, buying an estimated $86.8K and bringing the position to 141,812 shares worth $3.16M. The position accounts for 0.01% of the portfolio, ranked #537.

Bridgewater Associates first reported a position in ACAD in Q1 2022 and has held it in 5 quarters since. The position peaked at $3.69M in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Bridgewater Associates held 141,812 shares of Acadia Pharmaceuticals worth $3.16M as of Q1 2026.
  • Bridgewater Associates bought 3,633 Acadia Pharmaceuticals shares in Q1 2026, an estimated $86.8K.
  • Acadia Pharmaceuticals made up 0.01% of Bridgewater Associates's portfolio in Q1 2026, its #537 holding.
  • Bridgewater Associates first reported a position in Acadia Pharmaceuticals in Q1 2022 and has held it in 5 quarters since.
  • Bridgewater Associates's Acadia Pharmaceuticals position peaked at $3.69M in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.